Morizono Shusuke, Nakamura Makoto, Kohjima Motoyuki, Miyagi Izuru, Yoshimoto Tsuyoshi, Arimaura Eiichirou, Kotoh Kazuhiro, Enjoji Munechika, Soejima Yuji, Taketomi Akinobu, Yoshizumi Tomoharu, Uchiyama Hideaki, Shimada Mitsuo, Maehara Yoshihiko, Nawata Hajime
Department of Medicine III, Kyushu University Hospital, Fukuoka, Japan.
Fukuoka Igaku Zasshi. 2004 Dec;95(12):321-31.
To evaluate indications for living-donor liver transplantation (LDLT), we examined 25 consecutive patients with acute hepatic failure admitted to the Department of Medicine III, Kyushu University Hospital between November 2001 and July 2004. These cases were diagnosed as fluminant hepatitis (n=13), severe-type acute hepatitis (n=11), or late-onset hepatic failure (n=1). Nine patients (36%) improved with conservative treatment (conservative treatment group), and the other 16 patients (64%) needed LDLT (LDLT indicated group). In the LDLT indicated group, 11 patients received LDLT, and 4 died because of lack of LDLT donors (n=3), or renal failure (n=1). The LDLT survival rate was 82% (9/11); two patients died due to hepatic infarction and brain edema, respectively. It is very important to predict whether a patient with acute hepatic failure belongs to the conservative treatment group or the LDLT indicated group on admission. Therefore, we analyzed variables that could influence prognosis, including, parameters of hepatic function and platelet counts on admission, and relative hepatic volume (%), which represents the ratio of hepatic volume measured by CT relative to standard hepatic volume calculated with body surface area. Univariate logistic analysis showed that relative hepatic volume, gammaglutamyl transpeptidase (gamma-GTP), alkaline phosphatase (ALP), and the ratio of direct bilirubin to total bilirubin (DB/TB) were significant predictors of survival (p < 0.05). Using these factors plus prothrombin time (PT) and total cholesterol, both of which were relatively significant predictors of survival (p < 0.2), we proposed a model for predicting the probability of survival by the stepwise method. Consequently, we proposed a model using four parameters: ALP, GGTP, PT, and relative hepatic volume (Volume) as shown below: p(%) = 1/(1+exp (-(-36.2375 + ALP x 0.0251 + gamma-GTP x 0.0102 + PT x 0.2558 + Volume 21.2158))) x 100. This model showed a significant correlation between prediction and consequence of survival (r2 = 0.7388, p = 0.0003). In conclusion, LDLT is an effective treatment for acute hepatic failure. The results of this study suggested that our model can adequately predict prognosis in the early phase of acute hepatic failure.
为评估活体肝移植(LDLT)的适应证,我们对2001年11月至2004年7月间连续收治于九州大学医院内科三部的25例急性肝衰竭患者进行了研究。这些病例被诊断为暴发性肝炎(n = 13)、重型急性肝炎(n = 11)或迟发性肝衰竭(n = 1)。9例患者(36%)经保守治疗后病情改善(保守治疗组),另外16例患者(64%)需要进行LDLT(LDLT适应证组)。在LDLT适应证组中,11例患者接受了LDLT,4例患者因缺乏LDLT供体(n = 3)或肾衰竭(n = 1)死亡。LDLT的生存率为82%(9/11);2例患者分别死于肝梗死和脑水肿。在急性肝衰竭患者入院时预测其属于保守治疗组还是LDLT适应证组非常重要。因此,我们分析了可能影响预后的变量,包括入院时的肝功能参数、血小板计数以及相对肝体积(%),相对肝体积代表CT测量的肝体积与根据体表面积计算的标准肝体积之比。单因素逻辑回归分析显示,相对肝体积、γ-谷氨酰转肽酶(γ-GTP)、碱性磷酸酶(ALP)以及直接胆红素与总胆红素之比(DB/TB)是生存的显著预测指标(p < 0.05)。使用这些因素加上凝血酶原时间(PT)和总胆固醇,这两者都是相对显著的生存预测指标(p < 0.2),我们采用逐步法提出了一个预测生存概率的模型。因此,我们提出了一个使用四个参数的模型:ALP、GGTP、PT和相对肝体积(Volume),如下所示:p(%) = 1/(1 + exp(-(-36.2375 + ALP×0.0251 + γ-GTP×0.0102 + PT×0.2558 + Volume 21.2158)))×100。该模型显示预测结果与生存结果之间存在显著相关性(r2 = 0.7388,p = 0.0003)。总之,LDLT是治疗急性肝衰竭的有效方法。本研究结果表明,我们的模型能够在急性肝衰竭早期充分预测预后。